Medicine availability and affordability for paediatric cancers, China
2025

Access to Pediatric Cancer Medicines in China

Sample size: 55 publication 10 minutes Evidence: moderate

Author Information

Author(s): Lin Bai, Huang Tao, Li Huangqianyu, Shi Luwen, Denburg Avram, Gupta Sumit, Guan Xiaodong

Primary Institution: Peking University

Hypothesis

What is the availability and affordability of essential anticancer medicines for children in China?

Conclusion

Access to essential anticancer medicines for children remains suboptimal in China and varies across regions.

Supporting Evidence

  • 14 out of 33 medicines were available in less than 50% of hospitals.
  • 6 products had a median single-day copayment exceeding daily disposable income.
  • Median availability was higher for medicines approved for pediatric use (80.0%) compared to those without (48.2%).
  • 42.4% of medicines had both good availability and affordability.

Takeaway

This study looked at how easy it is for kids in China to get cancer medicines. It found that many medicines are hard to find and too expensive for families.

Methodology

Cross-sectional data on drug use was collected from 55 tertiary children's hospitals across seven regions in China.

Potential Biases

Potential overestimation of availability due to reliance on reported usage data.

Limitations

The study only included tertiary hospitals and did not differentiate between generic and brand-name drugs.

Participant Demographics

Children under 20 years old in China.

Statistical Information

P-Value

p<0.001

Statistical Significance

p<0.001

Digital Object Identifier (DOI)

10.2471/BLT.24.291640

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication